On the other hand, for the lower-risk population (in the 10th percentile and below), the MTP-BCR method reduces the false negative rate by 67–88% for patients who are misclassified as low-risk but will develop breast cancer within 10 years. This evidence concerns the gene BCR and breast carcinoma.